Trials / Unknown
UnknownNCT02585908
Safety and Efficacy of γδ T Cell Against Gastric Cancer
γδ T Cell Immunotherapy for Treatment of Gastric Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Beijing Doing Biomedical Co., Ltd. · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, safety and effects of γδT cells on human gastric cancer are going to be investigated.
Detailed description
PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and CIK, they will be infused to the patients as immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CIK | CIK cells will be used against tumor cells. |
| BIOLOGICAL | γδ T | γδ T cells will be used against tumor cells. |
| BIOLOGICAL | CIK and γδ T | CIK and γδ T cells will be used against tumor cells. |
Timeline
- Start date
- 2019-12-01
- Primary completion
- 2021-12-01
- Completion
- 2022-12-01
- First posted
- 2015-10-26
- Last updated
- 2019-11-13
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02585908. Inclusion in this directory is not an endorsement.